Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the provided transcript. The company is ahead of schedule in terms of debt repayment, with net debt at Rs. 2,500 crores at the end of Q2, against a year-end target of Rs. 2,600 crores. The focus is on strengthening the balance sheet and reducing debt rather than raising new debt. Capital expenditure guidance is Rs. 100-120 crores, and a Rs. 54 crore investment in Levim has been made for a 30% equity stake. No indications of raising funds through equity in the near term were stated. The company appears focus

Any current/future capex/capital investment/strategic investment?

Planned capital expenditure (CAPEX) of Rs. 100 to 120 crores for the financial year. Strategic investment of Rs. 54 crores for a 30% equity stake in Levim Lifetech. Levim investment aims to build a vertically integrated biologics presence and access to an exciting biologics product pipeline. Large-scale bulk manufacturing facility at Levim to be commissioned by mid next year. Levim's existing commercial products include Liraglutide API, Streptokinase, and Pegaspargase. New business segments such as Injectable CDMO for European markets and Oral Solid Dose exports planned to start contributing f

Future growth expectations in sales/revenue/volumes?

Domestic Branded Formulations (DBF) base business is tracking 9-10% growth for FY25, driven mainly by new product launches in H2. Insulin segment expected to grow strongly at 18-20% CAGR over the next 2-3 years despite some supply challenges. Swiss Parenterals business targeting Rs. 330 crore revenue this year, around 15% growth, with new segments like injectable CDMO and oral solids exports contributing from FY26 onwards. Injectable India business currently Rs. 7 crore/month, expected to improve significantly next year. Launch of GLP-1 drugs (Liraglutide and upcoming Semaglutide in 20

Future growth expectations in earnings/operating earnings/profits/EPS?

Consolidated Q2 revenue grew 47% to Rs. 741 crores; H1 revenue up 50% to Rs. 1,461 crores. Q2 EBITDA at Rs. 265 crores with 36% margin; 46% year-on-year growth; H1 EBITDA grew 47% to Rs. 515 crores. Operating cash flow was 119% of EBITDA in Q2. Adjusted ROCE improved by 400 bps to 23%; consolidated ROCE up 600 bps to 17%. Guidance for FY25: Domestic Branded Formulations revenue at Rs. 2,600 crores with 36% EBITDA margin; consolidated revenue Rs. 3,000 crores with 35% EBITDA margin. Net debt reduced to Rs. 2,500 crores, ahead of Rs. 2,600 crore target. New product launches expected to drive bas

IN US

Sale is live|00:00:00left today

ERIS Lifesciences LtdQ3 FY24Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,461P/E: 42.8Market Cap: ₹19.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Domestic Branded Formulations (DBF) base business is tracking 9-10% growth for FY25, driven mainly by new product launches in H2.
→Insulin segment expected to grow strongly at 18-20% CAGR over the next 2-3 years despite some supply challenges.
→Swiss Parenterals business targeting Rs. 330 crore revenue this year, around 15% growth, with new segments like injectable CDMO and oral solids exports contributing from FY26 onwards.
→Injectable India business currently Rs. 7 crore/month, expected to improve significantly next year.
→Launch of GLP-1 drugs (Liraglutide and upcoming Semaglutide in 2026) anticipated to be a game changer with substantial market growth.
→Vertical integration through Levim partnership expected to accelerate biologics pipeline and production capacity by mid-next year, enhancing long-term growth.
→Overall consolidated revenue guidance for FY25 is Rs. 3,000 crore with 35% EBITDA margin, with branded formulations at Rs. 2,600 crore and 36% margin.

Margin guidance

Category 3

→Consolidated Q2 revenue grew 47% to Rs. 741 crores; H1 revenue up 50% to Rs. 1,461 crores.
→Q2 EBITDA at Rs. 265 crores with 36% margin; 46% year-on-year growth; H1 EBITDA grew 47% to Rs. 515 crores.
→Operating cash flow was 119% of EBITDA in Q2.
→Adjusted ROCE improved by 400 bps to 23%; consolidated ROCE up 600 bps to 17%.
→Guidance for FY25: Domestic Branded Formulations revenue at Rs. 2,600 crores with 36% EBITDA margin; consolidated revenue Rs. 3,000 crores with 35% EBITDA margin.
→Net debt reduced to Rs. 2,500 crores, ahead of Rs. 2,600 crore target.
→New product launches expected to drive base business 9%-10% growth in H2FY25.
→Expansion in biologics and injectable segments, with new businesses contributing from FY26.
→EPS steady at Rs. 20 for H1FY25, with expectations to improve as new pipelines mature.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The company is ahead of schedule in terms of debt repayment, with net debt at Rs. 2,500 crores at the end of Q2, against a year-end target of Rs. 2,600 crores.
→The focus is on strengthening the balance sheet and reducing debt rather than raising new debt.
→Capital expenditure guidance is Rs. 100-120 crores, and a Rs. 54 crore investment in Levim has been made for a 30% equity stake.
→No indications of raising funds through equity in the near term were stated.
→The company appears focused on organic growth, acquisitions (e.g., Biocon businesses), and strategic partnerships funded with internal resources or planned investments.

Order book

Yes

The transcript provided does not explicitly mention the current or expected order book or pending orders for Eris Lifesciences Limited. However, relevant information that may relate to near-term business prospects includes: - Swiss Parenterals’ injectable export business has good visibility for FY25, with guided revenue of Rs. 330 crores (15% growth). - The new CDMO business targeting the European injectable market is expected to start contributing from FY26 onwards. - Oral Solid Dose (OSD) exports from the Ahmedabad plant are expected after Q4 FY25 or Q1 FY26 inspections and approvals. - The company anticipates growth led by several new product launches in H2 FY25, supporting base business expansion. - Levim partnership with Rs. 54 crore investment aims to scale up biologics product pipeline from mid-next year, indicating a strategic boost to future order inflow. No direct order backlog or pending order book figures were disclosed.

Capex plans

Yes

→Planned capital expenditure (CAPEX) of Rs. 100 to 120 crores for the financial year.
→Strategic investment of Rs. 54 crores for a 30% equity stake in Levim Lifetech.
→Levim investment aims to build a vertically integrated biologics presence and access to an exciting biologics product pipeline.
→Large-scale bulk manufacturing facility at Levim to be commissioned by mid next year.
→Levim's existing commercial products include Liraglutide API, Streptokinase, and Pegaspargase.
→New business segments such as Injectable CDMO for European markets and Oral Solid Dose exports planned to start contributing from FY 2026 onwards.
→Bhopal site starting insulin vial manufacturing from next month, expected to improve margins from Q4 FY25 / Q1 FY26.

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1ERIS Lifesciences Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like ERIS Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio